What Is Madrigal Pharmaceuticals, Inc. (MDGL) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Madrigal Pharmaceuticals, Inc.'s intrinsic value is estimated at $153.15. Trading at its current price of $536.86, the valuation engine raises significant caution: 12 of 12 models flag downside risk, projecting an average implied return of -71.5%. Notably, PWERM sees the most upside at -7.3% (fair value: $497.78), while ML-RIV is the most conservative at -98.6% ($7.73). The spread between these extremes — +91.3% — reveals how different analytical frameworks can reach starkly different conclusions. Among models with highest confidence, EPV, EROIC lean bearish — adding weight to the bearish side of the thesis.
What Do the Models Say About MDGL?
12 of 13 models are currently active for MDGL. All 12 active models suggest the stock trades above fair value. The Bayesian DCF estimates MDGL's intrinsic value at $170.21, implying -68.3% downside from the current price. See which stocks rank higher →
How Does MDGL Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, MDGL ranks #76 by Quality of Company score. CirclFi's QOC score of 6.8/10 evaluates 32 fundamental signals. A score of 6.8 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Madrigal Pharmaceuticals, Inc.'s positioning within the Pharmaceutical Preparations segment means that R&D productivity ratio plays an outsized role in fundamental analysis. The sector's unique characteristics — including licensing and M&A optionality — shape both the opportunity set and risk profile.
Is MDGL a Value Trap?
CirclFi's Value Trap algorithm assigns MDGL a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Madrigal Pharmaceuticals, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Madrigal Pharmaceuticals, Inc. earns a quality score of 6.8/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +91.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every MDGL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across MDGL's 12 active models, average confidence is 34%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad